MIT researchers reported on Oct. 26, 2026, in the journal Device that an implant they call LUCID combined a drug-delivery cannula with an array of 24 miniature ultrasound transducers, aiming to help drugs spread farther through brain tissue and bypass the blood-brain barrier. In tissue-phantom and mouse tests, ultrasound-aided delivery spread molecules farther than delivery without ultrasound; the mouse work used an MRI contrast agent.

The implant, roughly as thin as a sheet of cardstock, carries about 100 microliters of fluid, uses a passive osmotic pump and is controlled wirelessly via Bluetooth, with a rechargeable battery. The team framed the work as preclinical and hopes it could eventually help prevent glioblastoma recurrence if implanted during surgery, while noting it might also suit other drugs or soft tissues.

Glioblastoma is described as rare but deadly, with a little more than 10,000 U.S. cases annually and average survival of 12 to 15 months after diagnosis.